INTRODUCTION
Osteoporosis (OP) is one of the most common and costly diseases: one in every two women and one in five men will experience a fracture after the age of 50 years. 1 Hospitalisations for OP fracture are more common than hospitalisations for myocardial infarction and stroke combined 2 and fractures result in pain, immobility, nursing home placement, isolation and depression, in addition to other health problems. 1 Rheumatoid arthritis (RA) is a known risk factor for OP. 3 Ankylosing spondylitis (AS), despite its association with new bone formation and syndesmophytes, is also associated with vertebral OP and fractures.
While psoriatic arthritis (PsA) and psoriasis demonstrate a similar Th1-driven and Th17-driven inflammation to RA and a pathophysiological link to AS, few studies have addressed the risk of OP in these patients 4 5 Two studies have reported an increased prevalence of osteopenia or OP among patients with psoriasis in Taiwan and Israel. 6 7 Additional studies examined bone mineral density in patients with PsA compared with healthy controls, though with conflicting results. [8] [9] [10] [11] [12] These studies have been limited by cross-sectional designs and lack of adjustment for obesity, smoking or other risk factors for OP. To our knowledge, no studies have evaluated the risk of incident fracture in PsA or psoriasis. Therefore, the objective of this study was to examine the incidence of fracture in patients with PsA and psoriasis and compare this with matched controls from the general population and patients with RA.
METHODS

Study design
We performed a longitudinal cohort study to examine the risk of incident fracture among patients with psoriasis and PsA compared with patients from the general population and patients with RA.
Data source
Data from The Health Improvement Network (THIN) in the UK between 1994 and January 2014 were used.
35
Study population
All patients with PsA or psoriasis between the ages of 18 and 89 at the start date were included if they had observation time in THIN after Vision software implementation. Patients were excluded if they died or transferred out of the practice prior to the implementation of Vision software. Patients with a history of fracture or OP or a history of bisphosphonate prescriptions were excluded. Patients with psoriasis, PsA and RA were matched to up to five unexposed controls from the general population (matching is described in the online supplementary methods).
Exposure and outcome definitions
PsA, psoriasis and RA were defined by the presence of at least one read code consistent with these diseases using previously validated codes. [13] [14] [15] [16] [17] Severe psoriasis was defined as a code for psoriasis plus a code for either phototherapy or a systemic medication for psoriasis. The outcomes of interest were fractures (all fractures, hip fracture and vertebral fracture). [18] [19] [20] [21] Disease-modifying antirheumatic drugs (DMARDs) and covariates are listed in the online supplementary methods.
Person-time calculation
Cohort time started at the latest of the following: diagnosis with psoriasis, PsA or RA (diagnosis date For numbered affiliations see end of article.
for unexposed controls was the encounter date within 6 months of the matched patient's diagnosis date), 180 days after registration in the practice or Vision date (software implementation in the practice). Cohort time ended at earliest of development of the outcome, transfer out of the practice, practice stops contributing to THIN, death or the end of the study. All covariates of interest were measured prior to cohort entry.
Statistical analysis
Descriptive statistics were used to examine age, sex, person-time and covariate distribution between patients with PsA, psoriasis and unexposed controls. The number of events and cumulative incidence of fracture were calculated for each group. Cox proportional hazards models were used to calculate unadjusted and adjusted HRs with 95% CIs. A purposeful selection modelling approach was used to determine in the most biologically plausible and parsimonious model. 22 The proportional hazards assumption was assessed using log-log plots. Sensitivity analyses are described in the online supplementary data.
Ethics review
This study was approved by the University of Pennsylvania Institutional Review Board and the Cegedim Scientific Review Committee. This paper was prepared according to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. 23 
RESULTS
After applying inclusion and exclusion criteria, 9788 patients with PsA, 158 323 patients with psoriasis and 821 834 matched controls were identified. Baseline demographics are shown in table 1 and online supplementary table S1 . Time in the cohort was similar among the groups. Approximately 5% of patients with psoriasis had been prescribed a DMARD or received phototherapy. Oral corticosteroids were prescribed for 17% of patients with PsA, 21% of patients with severe 9% of patients with mild psoriasis and controls. Proton pump inhibitors were commonly prescribed for patients with PsA and severe psoriasis (31% each) than controls and those with mild psoriasis (both 15%). Patients with PsA and psoriasis were also more likely to have been prescribed an antidepressant in the baseline period and had a higher prevalence of diabetes than controls. Those with mild or severe psoriasis were more likely to be current smokers, while patients with PsA and severe psoriasis had higher rates of heavy alcohol use.
The number of events, unadjusted incidence per 10 000 person-years and HRs for fracture are presented in . These results were robust to several sensitivity analyses (see online supplementary tables S3 and S4). Defining fracture by a code for fracture followed by a bisphosphonate prescription resulted in slight increases in the HR. The results did not substantially change when patients with a history of fracture were included.
DISCUSSION
In this study, we found patients with PsA and psoriasis had an increased prevalence of risk factors for OP and fracture (eg, diabetes, alcohol abuse, smoking, depression, antidepressant use, corticosteroids, methotrexate and ciclosporin). [24] [25] [26] [27] [28] [29] Additionally, patients with PsA and psoriasis had an increased incidence of fracture compared with the general population by 7%-26%. The incidence of vertebral fracture was also increased in patients with severe psoriasis and while hip fracture was elevated in both psoriasis groups, it was only statistically significant in patients with mild psoriasis relative to matched controls after adjusting for risk factors for OP. We found that the risk for any fracture in patients with PsA and severe psoriasis was similar to RA. To our knowledge, these are the first population-based estimates of the risk for incident fracture and OP in patients with psoriasis and/or PsA and the first longitudinal cohort study to address this issue.
Strengths of this study include a large cohort of patients with an average of 6 years of follow-up; the use of THIN in which the exposures definitions (codes for PsA, RA, psoriasis) have been validated and fractures have been previously examined [13] [14] [15] [16] [17] ; and the ability to adjust for other measured risk factors for OP, including concomitant medications, body mass index and smoking. Additionally, inclusion of a cohort of patients with RA for internal comparison provides validity to the results as our estimates for RA were similar to previous studies. [30] [31] [32] Similarly, the incidence of hip fracture among controls in our study was similar to population statistics in the UK (10.7 vs 10.3 per 10 000 person-years), further supporting the validity of our results. 33 Finally, the HRs were robust to numerous sensitivity analyses.
Our study also has limitations. There is a risk for misclassification of the outcome when using diagnosis codes to define an event rather than imaging. We addressed this through sensitivity analyses in which we changed the outcome definition; this did not significantly change the results. We also used a secondary definition for fracture in which we required a therapy for OP to address osteoporotic fractures. Vertebral fracture may be underdiagnosed and thus under recorded. 24 We conducted a sensitivity analysis to examine whether observation bias affected these results and found no difference when we only included patients in the study followed at least once yearly. Next, disease manifestations, disease activity and use of biological DMARDs are not available in THIN, and therefore we were unable to directly examine their effects on risk of OP and fracture. We were also unable to account for some lifestyle factors such as degree of immobility or laboratory parameters such as vitamin D. Finally, the relatively small number of patients with PsA and/or severe psoriasis may have resulted in insufficient power for some of the outcomes, resulting in wide CIs that include 1.0 despite elevated point estimates (eg, for hip fracture among patients with severe psoriasis). 34 In conclusion, fractures, in particular osteoporotic fractures, are a major health problem that results in poor outcomes and OP is largely underdiagnosed. We found that similar to PsA and psoriasis (both mild and severe) were associated with an increased risk for fractures. Screening and management of OP should still be considered for patients with psoriasis and PsA using guidelines available for the general population.
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